- Home
- GHY vs FLGT Comparison
GHY vs FLGT Comparison
Compare GHY & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GHY | FLGT |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.0M | 697.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | GHY | FLGT |
|---|---|---|
| Price | $12.12 | $27.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 184.8K | ★ 265.4K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $315,549,000.00 |
| Revenue This Year | N/A | $16.84 |
| Revenue Next Year | N/A | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.61 |
| 52 Week Low | $10.24 | $14.57 |
| 52 Week High | $11.92 | $31.04 |
Technical Indicators
Market Signals| Indicator | GHY | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 33.16 | 47.00 |
| Support Level | $12.37 | $26.69 |
| Resistance Level | $12.47 | $31.04 |
| Average True Range (ATR) | 0.08 | 0.77 |
| MACD | -0.01 | -0.46 |
| Stochastic Oscillator | 5.41 | 10.80 |
Price Performance
Historical ComparisonAbout GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.